Home
About
Overview
History
Management Team
Board of Directors
Contact Us
Careers
Technology & Pipeline
Overview
Lantibiotics
LBP
Other Technologies
Collaborations
Overview
ECC - Lantibiotics
ECC - Oral Mucositis
News & Media
Press Releases
Presentations
Publications
Abstracts
Investors
Investor Relations
Overview
News / Events
Press Releases
Email Alerts
IR Calendar
Company Info
Profile
Presentations
Management Team
Contacts
FAQ
Financial Info
Financials
Financial Results
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Home
News & Media
Abstracts
News & Media
Press Releases
Presentations
Publications
Abstracts
Abstracts
Engineering Improved Variants of Mutacin 1140 by Saturation Mutagenesis
Development of OG716, a Novel Lantibiotic Against Clostridium difficile
